Immune checkpoint inhibitors are effective against non-small cell lung cancer in some patients. Researchers are investigating who benefits from the drugs and when they should be administered for maximum impact.
With the FDA’s approval of the first tumor‑infiltrating lymphocyte (TIL) therapy to treat advanced melanoma, researchers seek to expand this type of cellular therapy to other solid tumors.
The drug showed promise in treating small cell lung cancer that had progressed during or after chemotherapy.
The June edition of Editors’ Picks includes a clinical trial that clinched a new FDA approval for adagrasib, a new imaging modality to predict glioblastoma response, and more.
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
The editors of AACR's journals highlight studies from May, including machine learning, savings from quitting smoking, and more.
Researchers at the AACR Annual Meeting 2024 examined new treatment options for brain tumors.
Scientists thought pancreatic cancer wouldn’t respond to immunotherapy. Now research has found vaccines can trigger the immune system to fight the disease.
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More